Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial.

Cardiovascular diabetology·2026
Same author

The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial.

Journal of cardiac failure·2026
Same author

Optimizing the protocol for modified natural cycle frozen embryo transfer (mNC-FET): a multicentre, single-blinded randomized controlled trial.

Human reproduction open·2026
Same author

Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic Trial.

European journal of preventive cardiology·2026
Same author

No Effect of Low-Dose Aspirin Versus Placebo as Add-On Treatment in Bipolar Disorder-Results From a Randomised Controlled Trial (the A-Bipolar RCT).

Acta psychiatrica Scandinavica·2025
Same author

Oxidative stress in schizophrenia and bipolar disorders, results from a 2-year follow-up study of two prospective studies.

Free radical biology & medicine·2025
Same journal

Consensus by design: Conflict of interest and the intravenous ketamine Delphi guidelines.

Journal of affective disorders·2026
Same journal

Impaired crying despite preserved emotional experience under antidepressant treatment: An under-recognized clinical phenomenon.

Journal of affective disorders·2026
Same journal

Corrigendum to "Effects of neuronavigation-guided rTMS on serum BDNF, TrkB and VGF levels in depressive patients with suicidal ideation" [J. Affect. Disord. 323 (2023) 617-623].

Journal of affective disorders·2026
Same journal

Transcutaneous vagus nerve stimulation enhances reward-effort efficiency in severe major depressive disorder.

Journal of affective disorders·2026
Same journal

Age-varying associations between attitudes toward suicide and suicidal ideation in Chinese psychiatric outpatients.

Journal of affective disorders·2026
Same journal

Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Journal of affective disorders·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Antidepressants and dementia.

Lars Vedel Kessing1, Lars Søndergård, Julie Lyng Forman

  • 1Department of Psychiatry, University Hospital of Copenhagen, Rigshospitalet, Copenhagen Ø, Denmark. lars.kessing@rh.dk

Journal of Affective Disorders
|January 14, 2009
PubMed
Summary
This summary is machine-generated.

Long-term antidepressant use may reduce dementia risk, though not to general population levels. Initial prescriptions showed increased dementia rates, but continued treatment was associated with a lower rate.

More Related Videos

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Related Experiment Videos

Last Updated: Jun 26, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epidemiology

Background:

  • Antidepressants may possess neuroprotective properties.
  • Previous research has not extensively explored the link between antidepressant treatment and dementia risk reduction.

Purpose of the Study:

  • To investigate whether antidepressant treatment influences the risk of developing dementia.
  • To examine the association between antidepressant use and dementia incidence over time.

Main Methods:

  • Utilized Danish national registers to link antidepressant prescriptions with dementia diagnoses from 1995 to 2005.
  • Included a large cohort of individuals prescribed antidepressants and a comparison group unexposed to these medications.

Main Results:

  • Individuals with one antidepressant purchase showed a higher dementia rate compared to unexposed individuals.
  • Initial antidepressant prescriptions correlated with increased dementia rates, but long-term treatment was linked to a reduced rate.
  • This pattern held true across all antidepressant classes (SSRIs, newer non-SSRIs, older antidepressants) and in analyses focusing on Alzheimer's disease.

Conclusions:

  • Continued long-term antidepressant treatment is associated with a decreased rate of dementia.
  • The dementia rate among long-term antidepressant users remained higher than in the general population.
  • Methodological limitations due to the non-randomized data design cannot be ruled out as a factor in the findings.